Searched for: author%3A%22Fisher%2C+P.%22
(1 - 4 of 4)
document
Mazur, N. (author), Salviati, S. (author), Huinink, H. (author), Fina, A. (author), Carioso, A. (author), Fisher, P. (author), Adan, O. (author)
Thermochemical heat storage (TCHS) in salt hydrates attracts increasing interest due to the high energy density combined with loss-free storage. Strontium bromide hexahydrate (SBH), and composites thereof, are often suggested as suitable materials for this application. Although many aspects of SBH composites have been thoroughly investigated,...
article 2022
document
Schlunk, F. (author), Fisher, P. (author), Princen, H.M.G. (author), Rex, A. (author), Prinz, V. (author), Foddis, M. (author), Lütjohann, D. (author), Laufs, U. (author), Endres, M. (author)
Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PSCK9) neutralizing antibodies effectively lower plasma cholesterol levels and decrease cardiovascular events but also raised some concern that cognitive function could worsen as a side effect. Here, we performed experiments in mice to characterize the effect of anti-PCSK9 antibodies...
article 2021
document
Schlunk, F. (author), Fisher, P. (author), Princen, H.M.G. (author), Rex, A. (author), Prinz, V. (author), Foddis, M. (author), Lütjohann, D. (author), Laufs, U. (author), Endres, M. (author)
Anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies lower low-density lipoprotein cholesterol levels and significantly reduce cardiovascular end points.1 Safety concerns were raised as ultra-low levels of low-density lipoprotein cholesterol can be achieved. Low cholesterol levels are associated with an increased rate of...
article 2020
document
Hoek, G. (author), Fisher, P. (author), van den Brandt, P. (author), Goldbohm, S. (author), Brunekreef, B. (author), TNO Voeding (author)
article 2001
Searched for: author%3A%22Fisher%2C+P.%22
(1 - 4 of 4)